PDS Biotechnology Corp — Director's Dealing 2015

Oct 1, 2015

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Edge Therapeutics, Inc. (EDGE)
CIK: 0001472091
Period of Report: 2015-09-30

Reporting Person: BLECH ISAAC (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to purchase)	$2.39	2022-12-19	Common Stock (730940)		Direct
Stock Option (right to purchase)	$2.04	2023-10-11	Common Stock (11695)		Direct
Stock Option (right to purchase)	$8.28	2024-03-27	Common Stock (4385)		Direct
Stock Option (right to purchase)	$11	2025-09-30	Common Stock (21928)		Direct

Footnotes

F1: This option, representing a right to purchase a total of 730,940 shares of Common Stock, became exercisable on December 19, 2012 with 50% vesting on that date and the remaining 50% vesting in 16 equal quarterly installments thereafter beginning on July 31, 2013, subject to continued service as director through each vesting date.

F2: This option, representing a right to purchase a total of 11,695 shares of Common Stock, became exercisable on October 11, 2013 with 30% vesting on that date and the remaining 70% vesting in 14 equal quarterly installments thereafter, subject to continued service as director through each vesting date.

F3: This option, representing a right to purchase a total of 4,385 shares of Common Stock, became exercisable on June 1, 2013, with 25% vesting on that date and the remaining 75% vesting in 12 equal quarterly installments thereafter, subject to continued service as director through each vesting date.

F4: This option, representing a right to purchase a total of 21,928 shares of Common Stock, will become exercisable upon the earlier of the first anniversary of the date of grant or the issuer's next annual stockholders meeting, subject to continued service as director through the vesting date.